Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy
Japanese Journal of Ophthalmology · 2024-11 · 68 (6) · 660-668
DOI: 10.1007/s10384-024-01123-w ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Ophthalmology, online erschienen am 02.10.2024. Verfasst von Morio Ueno und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Endothelium, Corneal, Visual Acuity, Corneal Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
To evaluate the efficacy and safety of a cultured human corneal endothelial cell (cHCEC) product in eyes with bullous keratopathy (BK). Combined analysis of multicenter phase II and III clinical trials. This analysis involved 15 BK eyes in the phase II trial and 12 BK eyes in the phase III trial that underwent cHCEC transplant therapy. Safety was assessed in all the cases. Efficacy was assessed in 17 cases with exclusion of the low- and medium-dose groups in the phase II trial. The primary endpoint was a corneal endothelial cell density of 1000 cells/mm2 or more at 24 weeks post-transplant, which was attained in 94.1% of the eyes (16 of 17), with a 95% CI of 71.3-99.9%. Additionally, 82.4% of the eyes (14 of 17) met the secondary endpoint of reduction in corneal thickness to less than 630 µm without corneal epithelial edema within the same time frame, with a 95% CI of 56.6-96.2%. The mean decrease in corneal thickness from baseline to 24 weeks post-transplant was -187.4 µm (95% CI, -240.2 µm to -134.5 µm). Furthermore, all the eyes exhibited improvement in best-corrected visual acuity from baseline to 24 weeks post-transplant (95% CI, 80.5-100.0%). By 24 weeks post-transplant, 88.9% of the patients (24 of 27) had experienced adverse events, which were mostly local, mild, and transient. The cHCEC product of this study reconstitutes the corneal endothelial layer with high cellular density and restores corneal thickness and improves visual acuity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department for Medical Innovation and Translational Medical Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Ophthalmology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
- Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto, 602-0841, Japan. shigeruk@koto.kpu-m…
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Ueno, M., Imai, K., Tomioka, Y., Horiguchi, G., Kameda, T., Teramukai, S., Tsujikawa, A., Inatomi, T., Sotozono, C., & Kinoshita, S. (2024). Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy. Japanese Journal of Ophthalmology, 68(6), 660-668. https://doi.org/10.1007/s10384-024-01123-w
Vancouver
Ueno M, Imai K, Tomioka Y, Horiguchi G, Kameda T, Teramukai S, et al. Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy. Japanese Journal of Ophthalmology. 2024;68(6):660-668. doi:10.1007/s10384-024-01123-w
BibTeX
@article{Ueno2024,
author = {Ueno, Morio and Imai, Kojiro and Tomioka, Yasufumi and Horiguchi, Go and Kameda, Takanori and Teramukai, Satoshi and Tsujikawa, Akitaka and Inatomi, Tsutomu and Sotozono, Chie and Kinoshita, Shigeru},
title = {Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy},
journal = {Japanese Journal of Ophthalmology},
year = {2024},
volume = {68},
number = {6},
pages = {660--668},
doi = {10.1007/s10384-024-01123-w}
}
EUVIMED